DOCE Director Dr. Michael Schwartz has been awarded a 5-year NIH R01 for his project “Novel Anti-Diabetic Actions of Hypothalamic FGF19-FGFR1 Signaling”. The proposal stems from the finding by the Schwartz laboratory that FGF19 action in the brain rapidly, potently and selectively increases insulin-independent glucose disposal identifies a novel, CNS-driven mechanism with translational implications for both the pathogenesis and treatment of human diabetes. Studies in this proposal seek to clarify how this occurs and the extent to which it explains the anti-diabetic effect of bariatric surgical procedures.